APA141Hu04 100µg Active Plasminogen Activator, Urokinase Receptor (uPAR) Organism Species: *Homo sapiens* (Human) *Instruction manual*

FOR RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

13th Edition (Revised in Aug, 2023)

[PROPERTIES]

Source: Prokaryotic expression. Host: *E. coli* Residues: Leu13~Gly305 Tags: N-terminal His-tag Purity: >80% Endotoxin Level: <1.0EU per 1µg (determined by the LAL method). Buffer Formulation: PBS, pH7.4, containing 0.01% SKL, 5% Trehalose . Original Concentration: 200µg/mL Applications: Cell culture; Activity Assays. (May be suitable for use in other assays to be determined by the end user.) Predicted isoelectric point: 6.4 Predicted Molecular Mass: 35.9kDa Accurate Molecular Mass: 36&32kDa as determined by SDS-PAGE reducing conditions.

[<u>USAGE</u>]

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Cloud-Clone Corp.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCE]

LHTCVPAS WGLRCMQCKT NGDCRVEECA LGQDLCRTTI VRLWEEGEEL ELVEKSCTHS EKTNRTLSYR TGLKITSLTE VVCGLDLCNQ GNSGRAVTYS RSRYLECISC GSSDMSCERG RHQSLQCRSP EEQCLDVVTH WIQEGEEGRP KDDRHLRGCG YLPGCPGSNG FHNNDTFHFL KCCNTTKCNE GPILELENLP QNGRQCYSCK GNSTHGCSSE ETFLIDCRGP MNQCLVATGT HEPKNQSYMV RGCATASMCQ HAHLGDAFSM NHIDVSCCTK SGCNHPDLDV QYRSG

[ACTIVITY]

Urokinase-type plasminogen activator receptor (uPAR) is а glycosylphosphatidylinositol (GPI)-anchored protein. Besides regulating proteolysis, uPAR could also activate many intracellular signaling pathways that promote cell motility, invasion, proliferation and survival through cooperating with transmembrane receptors. uPAR is overexpressed across a variety of tumors and is associated with cancer invasion and metastasis. ITGb1 has been identified as an interactor of uPAR, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human uPAR and recombinant human ITGb1. Briefly, uPAR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 µ I were then transferred to ITGb1-coated microtiter wells and incubated for 1h at 37 °C. Wells were washed with PBST and incubated for 1h with anti-uPAR pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37 °C, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37 $^\circ$ C. Finally, add 50 μ L stop solution to the wells and read at 450/630 nm

Cloud-Clone Corp.

immediately. The binding activity of recombinant human uPAR and recombinant human ITGb1 was shown in Figure 1, the EC50 for this effect is 0.165 ug/mL.




Figure 1. The binding activity of recombinant human uPAR and recombinant human

ITGb1




Figure 2. Gene Sequencing (extract)

Cloud-Clone Corp.

kDa 70
44
33
26
22
18
14
10

Figure 3. SDS-PAGE

Sample: Active recombinant uPAR, Human

[IMPORTANT NOTE]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.